SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against NU SKIN ENTERPRISES INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 24, 2014 -- NUS


NEW YORK, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of investors who purchased Nu Skin Enterprises Inc. ("Nu Skin" or the "Company") (NYSE:NUS) common stock between July 10, 2013 and January 14, 2014.

For more information, click here: http://zlk.9nl.com/nuskin-enterprises-nus.

The complaint alleges that the Company made materially false and/or misleading statements and omitted materially adverse facts regarding the Company's business, operations, and prospects. In particular, it is alleged that the Company engaged in fraudulent sales practices and failed to comply with China's laws and regulations.

On January 15, 2014, shares of Nu Skin fell following a report in the Chinese newspaper People's Daily; this report alleges that Nu Skin's Chinese operations amount to a pyramid scheme and violate the laws of the People's Republic of China.

If you suffered a loss in Nu Skin you have until March 24, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/nuskin-enterprises-nus.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.



            

Contact Data